252 related articles for article (PubMed ID: 30454008)
21. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration.
Yu Y; Cui N; Li HY; Wu YM; Xu L; Fang M; Sheng Y
BMC Cancer; 2016 Oct; 16(1):808. PubMed ID: 27756234
[TBL] [Abstract][Full Text] [Related]
22. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
[TBL] [Abstract][Full Text] [Related]
23. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
[TBL] [Abstract][Full Text] [Related]
24. [Normalization in axillary lymph node management after neoadjuvant therapy for breast cancer].
Wu D; Liu SY; Amina M; Fan ZM
Zhonghua Wai Ke Za Zhi; 2019 Feb; 57(2):97-101. PubMed ID: 30704211
[TBL] [Abstract][Full Text] [Related]
25. Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study.
Aksoy SO; Sevinc Aİ; Ünal M; Balci P; Görkem İB; Durak MG; Ozer O; Bekiş R; Emir B
Medicine (Baltimore); 2020 Dec; 99(49):e23538. PubMed ID: 33285770
[TBL] [Abstract][Full Text] [Related]
26. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
[TBL] [Abstract][Full Text] [Related]
27. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
28. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
[TBL] [Abstract][Full Text] [Related]
29. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?
Cerbelli B; Botticelli A; Pisano A; Campagna D; De Vincentiis L; Pernazza A; Frusone F; Scavina P; Monti M; Fortunato L; Costarelli L; d'Amati G
Breast J; 2019 Mar; 25(2):273-277. PubMed ID: 30734420
[TBL] [Abstract][Full Text] [Related]
31. Risk stratification of patients with early breast cancer.
Roy PG; Chan SM; Ng V; Smith BM; Umeh H; Courtney SP
Clin Breast Cancer; 2014 Feb; 14(1):68-73. PubMed ID: 24252507
[TBL] [Abstract][Full Text] [Related]
32. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
Javid S; Segara D; Lotfi P; Raza S; Golshan M
Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
[TBL] [Abstract][Full Text] [Related]
33. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
[TBL] [Abstract][Full Text] [Related]
34. Is Breast Magnetic Resonance Imaging an Accurate Predictor of Nodal Status After Neoadjuvant Chemotherapy?
Cortina CS; Gottschalk N; Kulkarni SA; Karst I
J Surg Res; 2021 Jan; 257():412-418. PubMed ID: 32892139
[TBL] [Abstract][Full Text] [Related]
35. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
[TBL] [Abstract][Full Text] [Related]
36. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
37. Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?
Barrio AV; Mamtani A; Eaton A; Brennan S; Stempel M; Morrow M
Ann Surg Oncol; 2017 Mar; 24(3):645-651. PubMed ID: 28130619
[TBL] [Abstract][Full Text] [Related]
38. The clinical utility of combining pre-operative axillary ultrasonography and fine needle aspiration cytology with radionuclide guided sentinel lymph node biopsy in breast cancer patients with palpable axillary lymph nodes.
Usmani S; Ahmed N; Al Saleh N; abu Huda F; Amanguno HG; Amir T; al Kandari F
Eur J Radiol; 2015 Dec; 84(12):2515-20. PubMed ID: 26474908
[TBL] [Abstract][Full Text] [Related]
39. Sentinel node biopsy and neoadjuvant chemotherapy in the treatment of breast cancer.
Gatek J; Vrana D; Hnatek L; Bakala J; Dudesek B; Duben J; Musil T
J BUON; 2012; 17(2):265-70. PubMed ID: 22740204
[TBL] [Abstract][Full Text] [Related]
40. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
